Concepedia

Martin Winn

MW

30

Publications

1.1K

Citations

19

H-Index

1967

Active since

Affiliations

Abbott Fund(Current)

Abbott (United Kingdom)

Martin Winn is an author at Abbott Fund specializing in pharmacology, medicine, and drug discovery.

Top concepts

Publications per year

1967–2006

30

Publications

30

Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.

Terry J. Opgenorth, Andrew Adler, Samuel V. Calzadilla et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 209 citations

2,4-Diarylpyrrolidine-3-carboxylic AcidsPotent ET<sub>A</sub> Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722

Martin Winn, Thomas W von Geldern, Terry J. Opgenorth et al. · Journal of Medicinal Chemistry · 1996 · 110 citations · Full text

, , +12

Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 4. Side Chain Conformational Restriction Leads to ET<sub>B</sub> Selectivity

Thomas W von Geldern, Andrew S. Tasker, Bryan K. Sorensen et al. · Journal of Medicinal Chemistry · 1999 · 90 citations · Full text

, , +16

Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors

Bryan K. Sorensen, Martin Winn, Jeff Rohde et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 64 citations · Full text

, , +8

Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: <i>ex vivo</i> and <i>in vivo</i> studies

Jerry L. Wessale, Andrew Adler, Eugene I. Novosad et al. · Clinical Science · 2002 · 61 citations

Rows per page

1–5 of 30